Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | cytochrome P450, family 1, subfamily A, polypeptide 2 | Starlite/ChEMBL | References |
Homo sapiens | protein tyrosine kinase 2 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 2, subfamily C, polypeptide 8 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 2, subfamily D, polypeptide 6 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 2, subfamily C, polypeptide 19 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 2, subfamily C, polypeptide 9 | Starlite/ChEMBL | References |
Homo sapiens | cytochrome P450, family 3, subfamily A, polypeptide 4 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | cytochrome P450 | cytochrome P450, family 2, subfamily D, polypeptide 6 | 497 aa | 425 aa | 32.0 % |
Brugia malayi | cytochrome P450 | cytochrome P450, family 3, subfamily A, polypeptide 4 | 502 aa | 492 aa | 24.2 % |
Leishmania major | cytochrome p450-like protein | cytochrome P450, family 2, subfamily C, polypeptide 19 | 490 aa | 411 aa | 23.1 % |
Brugia malayi | Cytochrome P450 family protein | cytochrome P450, family 1, subfamily A, polypeptide 2 | 516 aa | 470 aa | 26.2 % |
Mycobacterium tuberculosis | Probable cytochrome P450 136 Cyp136 | cytochrome P450, family 2, subfamily C, polypeptide 9 | 490 aa | 441 aa | 21.8 % |
Mycobacterium tuberculosis | Probable cytochrome P450 136 Cyp136 | cytochrome P450, family 2, subfamily C, polypeptide 8 | 490 aa | 435 aa | 22.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | cytochrome P450, putative | 0.0036 | 0 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0157 | 0.0785 | 0.5 |
Leishmania major | cytochrome p450-like protein | 0.0036 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0157 | 0.0785 | 0.0785 |
Echinococcus multilocularis | beta adrenergic receptor kinase | 0.0161 | 0.081 | 0.003 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0157 | 0.0785 | 0.5 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0095 | 0.0381 | 0.0381 |
Loa Loa (eye worm) | G protein signaling regulator EGL-10 | 0.0157 | 0.0785 | 0.0785 |
Schistosoma mansoni | tyrosine kinase | 0.0305 | 0.1752 | 0.1049 |
Trypanosoma cruzi | cytochrome P450, putative | 0.0036 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0157 | 0.0785 | 0.0785 |
Brugia malayi | Cytochrome P450 family protein | 0.0095 | 0.0381 | 0.0381 |
Loa Loa (eye worm) | hypothetical protein | 0.0157 | 0.0785 | 0.0785 |
Loa Loa (eye worm) | AGC/GRK/BARK protein kinase | 0.0161 | 0.081 | 0.081 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0157 | 0.0785 | 0.5 |
Loa Loa (eye worm) | TK/FAK protein kinase | 0.0309 | 0.1775 | 0.1775 |
Brugia malayi | PXA domain containing protein | 0.0157 | 0.0785 | 0.0785 |
Brugia malayi | regulator of G-protein signaling egl-10 | 0.0157 | 0.0785 | 0.0785 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0161 | 0.081 | 0.0027 |
Loa Loa (eye worm) | hypothetical protein | 0.0157 | 0.0785 | 0.0785 |
Brugia malayi | Regulator of G protein signaling domain containing protein | 0.0157 | 0.0785 | 0.0785 |
Brugia malayi | Regulator of G protein signaling domain containing protein | 0.0157 | 0.0785 | 0.0785 |
Echinococcus granulosus | [G-protein-coupledreceptor] kinase | 0.1415 | 0.8979 | 1 |
Trypanosoma brucei | cytochrome P450, putative | 0.0036 | 0 | 0.5 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0157 | 0.0785 | 0.5 |
Brugia malayi | hypothetical protein | 0.0157 | 0.0785 | 0.0785 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0157 | 0.0785 | 0.5 |
Loa Loa (eye worm) | RGS-3 protein | 0.0157 | 0.0785 | 0.0785 |
Brugia malayi | hypothetical protein | 0.0157 | 0.0785 | 0.0785 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0157 | 0.0785 | 0.5 |
Mycobacterium ulcerans | cytochrome P450 185A4 Cyp185A4 | 0.0036 | 0 | 0.5 |
Echinococcus granulosus | beta-adrenergic receptor kinase | 0.0161 | 0.081 | 0.003 |
Schistosoma mansoni | serine/threonine protein kinase | 0.1572 | 1 | 1 |
Loa Loa (eye worm) | G protein-coupled receptor kinase 1 | 0.1415 | 0.8979 | 0.8979 |
Loa Loa (eye worm) | hypothetical protein | 0.0157 | 0.0785 | 0.0785 |
Trichomonas vaginalis | regulator of G protein signaling 5, rgs5, putative | 0.0157 | 0.0785 | 0.5 |
Echinococcus multilocularis | protein tyrosine kinase | 0.0305 | 0.1752 | 0.118 |
Loa Loa (eye worm) | AGC/GRK/GRK protein kinase | 0.1572 | 1 | 1 |
Brugia malayi | A-kinase anchor protein 10, precursor | 0.0157 | 0.0785 | 0.0785 |
Loa Loa (eye worm) | AGC/GRK/GRK protein kinase | 0.1415 | 0.8979 | 0.8979 |
Brugia malayi | PXA domain containing protein | 0.0157 | 0.0785 | 0.0785 |
Brugia malayi | Probable G protein-coupled receptor kinase F19C6.1, putative | 0.1415 | 0.8979 | 0.8979 |
Brugia malayi | Protein kinase domain containing protein | 0.0309 | 0.1775 | 0.1775 |
Echinococcus multilocularis | G protein coupled receptor kinase 6 | 0.1415 | 0.8979 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0157 | 0.0785 | 0.0785 |
Echinococcus granulosus | protein tyrosine kinase | 0.0305 | 0.1752 | 0.118 |
Entamoeba histolytica | hypothetical protein | 0.0157 | 0.0785 | 0.5 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0161 | 0.081 | 0.0027 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0157 | 0.0785 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0157 | 0.0785 | 0.5 |
Loa Loa (eye worm) | PXA domain-containing protein | 0.0157 | 0.0785 | 0.0785 |
Brugia malayi | regulator of G-protein signaling rgs-7 | 0.0157 | 0.0785 | 0.0785 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Fu (ADMET) | = 0.3 % | Fraction unbound in mouse serum | ChEMBL. | 23973211 |
Fu (ADMET) | = 0.35 % | Fraction unbound in human serum | ChEMBL. | 23973211 |
IC50 (ADMET) | = 4.8 uM | Inhibition of CYP2D6 (unknown origin) | ChEMBL. | 23973211 |
IC50 (ADMET) | > 10 uM | Inhibition of CYP3A4 (unknown origin) | ChEMBL. | 23973211 |
IC50 (ADMET) | > 10 uM | Inhibition of CYP2C19 (unknown origin) | ChEMBL. | 23973211 |
IC50 (ADMET) | > 10 uM | Inhibition of CYP2C9 (unknown origin) | ChEMBL. | 23973211 |
IC50 (ADMET) | > 10 uM | Inhibition of CYP2C8 (unknown origin) | ChEMBL. | 23973211 |
IC50 (ADMET) | > 10 uM | Inhibition of CYP1A2 (unknown origin) | ChEMBL. | 23973211 |
IC50 (binding) | > 10 uM | Inhibition of FAK (unknown origin) using biotinylated-His-TEVhsFAK(31-686)(K454R) as substrate after 2 hrs by scintillation counting analysis | ChEMBL. | 23973211 |
Kd (binding) | = 4 uM | Binding affinity to FAK kinase (unknown origin) by surface plasmon resonance assay | ChEMBL. | 23973211 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.